Oppenheimer & Co.

Oppenheimer & Co. is out with a research report on Zalicus Inc. (NASDAQ: ZLCS) and is lowering its price target to $3 from $4, but is keeping its Overweight rating on shares. In a note to clients, Oppenheimer & Co. writes, "We are providing an update on our view of Zalicus following a...

Oppenheimer & Co. is out with a research report on Alexion Pharmaceuticals (NASDAQ: ALXN) and it is raising its price target to $74 from $63, and it has an Outperform rating on shares. In anote to clients, Oppenheimer writes, "Following Soliris ph.II results in severe/refractory generalized...

Oppenheimer & Co. is out with a research report on Church & Dwight (NYSE: CHD) and is reiterating its Outperform rating and is raising its price target to $50 from $44. In a note to clients, Oppenheimer & Co. writes, "We are raising our target price on CHD owing largely to an...

Oppenheimer & Co. is out with a research report on Immunomedics Inc. (NASDAQ: IMMU) and it has an Outperform rating and a $6 price target on shares. In a note to clients, Oppenheimer & Co. writes, "Yesterday Immunomedics announced that its clinical study of clivatuzumab in pancreatic...

Oppenheimer & Co. is out with a research report on Red Hat (NYSE: RHT) and it has an Outperform rating and a $50 price target on shares following earnings. In a note to clients, Oppenheimer & Co. writes, "RHT posted impressive 2Q12 results, highlighted by 30% billings, 28% revenue, and 20...

Oppenheimer & Co. is out with a research report on SandRidge Permian Trust (NYSE: PER) and it has an Outperform rating and a $24 price target on shares. In a note to clients, Oppenheimer & Co. writes, "We initiate coverage of SandRidge Permian Trust with an Outperform rating and $24 price...

Oppenheimer & Co. is out with a research report on Alexion Pharmaceuticals (NASDAQ: ALXN) and it has an Outperform rating and a $63 price target on shares. In a note to clients, Oppenheimer & Co. writes, "On 9/14, ALXN reported ph.II results for Soliris in severe/refractory generalized...

Oppenheimer & Co. is out with a research report on Incyte (NASDAQ: INCY) and it has an Outperform rating and a $25 price target on shares. In a note to clients, Oppenheimer writes, "On 9/14, we hosted a meeting with INCY that reaffirmed our confidence in ruxolitinib's potential in...

Oppenheimer & Co. Inc released a research report on HCA Holdings Inc. (NYSE: HCA) providing more clarity around operational trends and reiterating its Outperform rating. In the report, Oppenheimer & Co. writes, “HCA reported strong y-y revenue and volume growth for the two months ended Aug...

Oppenheimer & Co. is out with a research report on QR Energy (NYSE: QRE) and it has an Outperform rating and a $23 price target on shares. In a note to clients, Oppenheimer & Co. writes, "QRE announced a $577M dropdown from its sponsor and also announced attractive, low-cost financing...

Oppenheimer is out with a research report on Broadcom (NASDAQ: BRCM) and it has an Outperform rating and a $55 price target on shares. In a note to clients, Oppenheimer writes, "We are reiterating our Outperform rating and $55 PT following BRCM's announced acquisition of NETL for $50/shr or $3.7B...

Oppenheimer & Co. is out with a research report on Lululemon Athletica Inc. (NASDAQ: LULU) and it has a Perform rating on shares after it reported earnings. In a note to clients, Oppenheimer & Co. writes, "LULU reported F2Q11 diluted EPS of $0.26, above our/consensus (and split-adjusted...

Oppenheimer is out with a research report on Verint Systems (NASDAQ: VRNT) and is reiterating its Outperform rating and a $45 price target on shares. In a note to clients, Oppenheimer writes, "For 2Q11 (July), VRNT delivered solid results as key secular trends continue to drive demand. And,...

Oppenheimer & Co. is out with a research report on IDEX Corporation (NYSE: IEX) and is lowering its price target to $50 from $55, but is keeping its Overweight rating. In a note to clients, Oppenheimer & Co. writes, "We attended meetings with IEX CFO Heath Mitts and discussed an overview...

Oppenheimer & Co. is out with a research report on IDEX Corporation (NYSE: IEX) and it has an Outperform rating and a $50 price target on shares. In a note to clients, Oppenheimer & Co. writes, "We attended meetings with IEX CFO Heath Mitts and discussed an overview of the company's long-...